Anika Therapeutics (ANIK) Share-based Compensation (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Share-based Compensation data on file, last reported at $6.6 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $6.6 million, up 131.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.3 million (down 2.72% YoY), and the FY2025 annual result was $10.2 million, down 22.19% from the prior year.
• Share-based Compensation advanced to $6.6 million in Q1 2026 per ANIK's latest filing, from $2.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $6.6 million in Q1 2026 and troughed at -$132000.0 in Q3 2025.
• A 5-year average of $3.3 million and a median of $3.4 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation slumped 103.89% in 2025, then jumped 131.96% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $3.8 million in 2022, then grew by 0.05% to $3.8 million in 2023, then tumbled by 40.89% to $2.3 million in 2024, then increased by 14.86% to $2.6 million in 2025, then jumped by 156.41% to $6.6 million in 2026.
• Business Quant data shows ANIK's Share-based Compensation at $6.6 million in Q1 2026, $2.6 million in Q4 2025, and -$132000.0 in Q3 2025.